Ann: Appendix 4D and Half Year Financial Report, page-4

Bristol Myers Squibb, freshly armed with an approval for its CAR-T lymphoma therapy Breyanzi, is making a major cell therapy manufacturing play.
The company is building out a new 244,000-square-foot cell therapy site, housed at the company's 89-acre campus in Devens, Massachusetts. The new factory will be kitted out to quickly ramp up clinical and commercial production, augmenting Bristol's existing cell therapy manufacturing operations in Washington, New Jersey, the European Union and Japan.
The move comes just weeks after Bristol Myers' CAR-T med Breyanzi won an FDA green light in adults with relapsed or refractory large B-cell lymphoma—and as the company is anticipating a U.S. approval for another CAR-T therapy, ide-cel, in multiple myeloma.
Cell therapy manufacturing is a tricky beast, Bristol Myers admits:
Treatments have to be individually manufactured for each patient, using a person's own T-cells as the starting material. Each batch of engineered T-cells is then made for infusion into the original cancer patient, highlighting the need for quick manufacturing turnarounds.